StockDuty ← Dashboard Nov 15, 2026 09:19 PM ET
SignalEU/UK

Novo Nordisk reports additional CagriSema weight-loss findings. The stock trades on next-gen obesity data, so any incremental read on efficacy or tolerability matters more than the headline itself.

Novo Nordisk reports additional CagriSema weight-loss findings.

Novo Nordisk reports additional CagriSema weight-loss findings.
Novo Nordisk reports additional CagriSema weight-loss findings. — impact context not separately stored; see What changed.
Sources